Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 3/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565017 | 0.87 | QRFPR (0.52) | QRFPRSMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL7568582 | 0.86 | QRFPR (0.46) | QRFPRPDE4BSMN1; SMN2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL7570402 | 0.86 | QRFPR (0.51) | QRFPRSMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL7973639 | 0.85 | QRFPR (0.46) | QRFPRPDE4BSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7599133 | 0.85 | ALDH1A1 (0.40) | QRFPRPDE4BUTS2RALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL7562290 | 0.85 | QRFPR (0.45) | QRFPRPDE4BSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7570044 | 0.84 | ALDH1A1 (0.50) | QRFPRSMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL7565602 | 0.84 | QRFPR (0.46) | QRFPRPDE4BUTS2RSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7566301 | 0.83 | QRFPR (0.46) | QRFPRPDE4BUTS2RSMN1; SMN2ALDH1A1 | |
| SCHEMBL7562336 | 0.82 | QRFPR (0.45) | QRFPRPDE4BSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | claimed |
| WO-2001046170-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001046170-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | OPRM1, HIF1AN, MAOB | QRFPR 1733/4885PDE4B 570/4885UTS2R 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.